Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ALO-02

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
Proper management of severe pain represents one of the most challenging clinical dilemmas. Two equally important goals must be… Expand
  • figure 1
  • table 1
  • table 2
2017
2017
Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
Abstract Objective. To evaluate the abuse potential of ALO-02, an abuse-deterrent formulation comprising pellets of extended… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Review
2017
Review
2017
Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe…
BackgroundThe efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone… Expand
  • table 1
  • table 2
  • table 3
2015
2015
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain…
Abstract The objective of this multicenter, double-blind, placebo-controlled, randomized withdrawal study was to evaluate the… Expand
2015
2015
Intranasal administration of crushed ALO‐02 (extended‐release oxycodone with sequestered naltrexone): A randomized, controlled abuse‐potential study in nondependent recreational opioid users
ALO‐02 is an abuse‐deterrent formulation consisting of capsules filled with pellets of extended‐release oxycodone surrounding… Expand
2015
2015
Effects of Ethanol on the Pharmacokinetics of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02)
Background and ObjectivesALO-02 capsules, intended to deter abuse, contain pellets of extended-release oxycodone hydrochloride… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
2015
2015
Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO‐02, an extended release formulation of oxycodone with sequestered naltrexone
ALO‐02 is being developed as an abuse‐deterrent formulation of extended‐release oxycodone hydrochloride with naltrexone… Expand
Review
2014
Review
2014
Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options
Abstract Background: For properly selected patients experiencing chronic pain, extended-release opioid formulations may represent… Expand
2014
2014
A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic…
OBJECTIVE To evaluate the long-term safety of oxycodone-hydrochloride and sequestered naltrexone-hydrochloride (ALO-02… Expand
Review
2014
Review
2014
Relative Bioavailability Study of an Abuse-Deterrent Formulation ofExtended-Release Oxycodone with Sequestered Naltrexone (ALO-02)Versus Immediate-Release Oxycodone Tablets in Healthy Volunteers
Background: ALO-02, an opioid formulation intended to deter abuse, comprising capsules filled with pellets of extended-release… Expand
  • table 1
  • table 2
  • figure 2
  • table 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE